Quarterly ResultMay 14, 2026, 07:52 AM
Karyopharm Raises Going Concern Doubt; Q1 Net Loss $(22.4)M
AI Summary
Karyopharm Therapeutics Inc. reported a net loss of $(22.4) million for Q1 2026, an improvement from $(23.5) million in Q1 2025, with total revenue increasing to $35.1 million. However, the company disclosed substantial doubt about its ability to continue as a going concern within the next year, citing dependence on additional funding or strategic alternatives. The company raised $49.8 million in net cash from financing activities, including an open market sale and a private placement offering.
Key Highlights
- Substantial doubt raised about Karyopharm's ability to continue as a going concern.
- Net loss for Q1 2026 was $(22.4) million, an improvement from $(23.5) million in Q1 2025.
- Total revenue increased 16.8% to $35.1 million in Q1 2026 from $30.0 million year-over-year.
- Product revenue, net, grew 38.5% to $29.2 million in Q1 2026.
- Net cash provided by financing activities was $49.8 million in Q1 2026.
- Cash and cash equivalents increased to $90.9 million as of March 31, 2026.
- Diluted net loss per share improved to $(1.24) from $(2.77) year-over-year.